Paragon 28, Inc. (FNA) News

Paragon 28, Inc. (FNA): $15.18

-0.01 (-0.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter FNA News Items

FNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FNA News Highlights

  • FNA's 30 day story count now stands at 6.
  • Over the past 5 days, the trend for FNA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about FNA are ATRC, SI and SIBN.

Latest FNA News From Around the Web

Below are the latest news stories about Paragon 28 Inc that investors may wish to consider to help them evaluate FNA as an investment opportunity.

What Type Of Shareholders Make Up Paragon 28, Inc.'s (NYSE:FNA) Share Registry?

If you want to know who really controls Paragon 28, Inc. ( NYSE:FNA ), then you'll have to look at the makeup of its...

Yahoo | January 15, 2022

Paragon 28 acquires Disior Oy for $18M

Paragon 28 (FNA) has acquired Finland based Disior Oy., a leading three-dimensional analytics pre-operative planning software company focused on the complex foot and ankle…

Seeking Alpha | January 12, 2022

Paragon 28 Announces Acquisition of Disior

ENGLEWOOD, Colo., January 12, 2022--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "P28"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the acquisition of Disior Oy., a leading three-dimensional analytics pre-operative planning software company based in Helsinki, Finland, focused on the complex foot and ankle anatomy.

Yahoo | January 12, 2022

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atricure (ATRC – Research Report), SI-Bone (SIBN – Research Report) and Paragon 28 (FNA – Research Report) with bullish sentiments. Atricure (ATRC) In a report released today, Marie Thibault from BTIG maintained a Buy rating on Atricure, with a price target of $94.00. The company's shares closed last Friday at $61.62. According to TipRanks.

Brian Anderson on TipRanks | January 10, 2022

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021

ENGLEWOOD, Colo., January 10, 2022--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "P28"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2021.

Yahoo | January 10, 2022

FDA Approves Paragon 28 R3ACT Stabilization System; Shares Gain

Shares of Paragon 28, Inc. (NYSE: FNA) rose 1.3% to close at $16.66 on Wednesday after the medical device company revealed that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its R3ACT Stabilization System.   The Stabilization System, which is expected to be commercially available in early 2022, will complement Paragon 28’s ankle fracture and soft tissue portfolio. Furthermore, it will expand the company’s product offering in the foot and ankle orthopedic market.   Markedly, the company's comprehensive portfolio will provide clients with numerous innovative solutions for fracture repair and soft tissue stabilization.

Priti Ramgarhia on TipRanks | December 30, 2021

Paragon 28, Inc. R3ACT™ Stabilization System Cleared by FDA

ENGLEWOOD, Colo., December 29, 2021--Paragon 28, Inc. (NYSE: FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its R3ACT™ Stabilization System. The R3ACT™ Stabilization System, expected to commercially launch in early 2022, will complement Paragon 28’s comprehensive ankle fracture and soft tissue portfolio and further expands Parag

Yahoo | December 29, 2021

Contrasting NeuroMetrix (NASDAQ:NURO) & Paragon 28 (NYSE:FNA)

NeuroMetrix (NASDAQ:NURO) and Paragon 28 (NYSE:FNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends. Earnings & Valuation This table compares NeuroMetrix and Paragon 28s gross revenue, earnings per share and []

Dakota Financial News | December 23, 2021

Paragon 28 to Present at 24th Annual Needham Growth Conference

ENGLEWOOD, Colo., December 16, 2021--Paragon 28, Inc. (NYSE: FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will virtually present at the 24th Annual Needham Growth Conference on Monday, January 10th.

Yahoo | December 16, 2021

Paragon 28’s Patient Specific Titanium Talus Spacer Has Been Approved by the U.S. Food and Drug Administration

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufactured in titanium alloy with a titanium nitride coating. The Patient Specific Talus Spacer was first approved on February 17, 2021, by the FDA under a Humanitarian Device Exemption

Business Wire | December 13, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4345 seconds.